Determination of Residual Nitrilase in Brivaracetam Using Characteristic Peptides by Liquid Chromatography–Mass Spectrometry
Rapid Communications in Mass Spectrometry · 15.09.2026 · 40 (17)
DOI: 10.1002/rcm.70126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, online erschienen am 19.06.2026. Verfasst von Xueting Dai und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China. Hauptthemen laut MEDLINE: Liquid Chromatography-Mass Spectrometry, Pyrrolidinones, Tandem Mass Spectrometry, Aminohydrolases. Die Arbeit nennt 27 Literaturangaben. Gefördert von: National Key R&D Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Rationale
Nitrilases are widely used as biocatalysts in pharmaceutical manufacturing because of their high stereoselectivity and mild reaction conditions. However, residual nitrilase in final drug products may compromise product quality and safety, highlighting the need for sensitive and reliable analytical methods for its monitoring and control.
Methods
In this study, a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for the determination of residual nitrilase in pharmaceutical formulations.
Results
Recombinant nitrilase expressed in Escherichia coli was purified by Ni 2+ affinity chromatography and lyophilized prior to analysis. Following systematic optimization of digestion and chromatographic conditions, the method achieved a detection limit of 0.17 μg/g. The LC–MS/MS method was successfully applied to the analysis of brivaracetam samples at a concentration of 2000 μg/g, with residual nitrilase levels consistently below 85 μg/g, meeting relevant quality control requirements.
Conclusions
In this study, a sensitive and reliable LC–MS/MS method was developed for the determination of residual nitrilase in brivaracetam. The proposed method may serve as a general analytical strategy for quality control of nitrilase‐related pharmaceutical products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China.
- Division of Chemical Metrology & Analytical Science, National Institute of Metrology, Beijing, China.
- School of Pharmacy, China Medical University, Shenyang, China.
ORCID-Profile: Ming Li
Förderung
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Dai, X., Xu, K., Zhang, T., Li, M., Wu, P., Cheng, J., & Chen, H. (2026). Determination of Residual Nitrilase in Brivaracetam Using Characteristic Peptides by Liquid Chromatography–Mass Spectrometry. Rapid Communications in Mass Spectrometry, 40(17). https://doi.org/10.1002/rcm.70126
Vancouver
Dai X, Xu K, Zhang T, Li M, Wu P, Cheng J, et al. Determination of Residual Nitrilase in Brivaracetam Using Characteristic Peptides by Liquid Chromatography–Mass Spectrometry. Rapid Communications in Mass Spectrometry. 2026;40(17). doi:10.1002/rcm.70126
BibTeX
@article{Dai2026,
author = {Dai, Xueting and Xu, Kongliang and Zhang, Tianji and Li, Ming and Wu, Peize and Cheng, Jinlan and Chen, Hanrui},
title = {Determination of Residual Nitrilase in Brivaracetam Using Characteristic Peptides by Liquid Chromatography–Mass Spectrometry},
journal = {Rapid Communications in Mass Spectrometry},
year = {2026},
volume = {40},
number = {17},
doi = {10.1002/rcm.70126}
}
EUVIMED